In a published interview, Novartis (NVS) CEO said the company has increased its stockpiles of pharmaceuticals in the U.S. and is prepared in case its products are subject to President Donald Trumps’ tariffs, Reuters reports.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVS:
- Novartis looking into price cut proposals for U.S., Bloomberg reports
- Tesla CEO buys shares, China says Nvidia broke antitrust law: Morning Buzz
- Monte Rosa’s Stock (GLUE) Skyrockets on $5.7B Deal with Novartis
- Monte Rosa Therapeutics announces collaboration with Novartis
- Trump Weekly: Trump signs pharma order, FTC opens inquiry into AI chatbots